Dynasil Corp Of America · OTC:DYSL
Dynasil Corp Of America — Dynasil Corporation of America — Shareholder Meeting (February 2015)
20 slides from Dynasil Corp Of America's shareholder meeting presentation, Feb 26, 2015
Slide 1: Xcede Technologies, Inc. Dynasil Corporation of America Annual Meeting of Stockholders
Xcede Technologies, Inc. Dynasil Corporation of America Annual Meeting of Stockholders Peter Sulick, Chairman, President and CEO February 26, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements The statements made in this presentation which are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve kn
Slide 3: Xcede Technologies Introduction
Xcede Technologies Introduction Xcede Technologies has developed a game changing hemostat sealant patch which differentiates itself due to its adhesive capability and ability to be used on high pressure arterial bleeding. 3
Slide 4: Xcede Technologies’ Value Proposition
Xcede Technologies’ Value Proposition •Superior technology •Large and growing market-$5.5 Billion •Extremely low manufacturing costs •Alone in its ability to be used on very high pressure bleeding •Predictable and known development pathway •Partnership with Mayo Clinic •Industry with acquisition mom
Slide 5: Our Solution: The Xcede Patch Version 2.0
Our Solution: The Xcede Patch Significant research and development has resulted in multiple formations of the patch (version 1.0 and version 2.0) resulting in its present configuration of a preformed 4”x4” two layer patch consisting of a fibrin mesh with proprietary adhesive backing. Version 2.0 H
Slide 6: Current Xcede Technologies’ Team
Current Xcede Technologies’ Team Management Board of Directors Vic Schmitt Dave Talen - CEO 20 years of marketing, sales and general management Peter Sulick experience in the Medical Device Industry. Sarah Combs Management positions at Scimed Life Systems, Integ, Urologix, Spinetech and Timm Med
Slide 7: Strategy
Strategy • Launch the Xcede patch first in Europe and then in the US with initial indication for General Surgery in mild to moderate bleeding. • First in human clinical trial and pilot data • FDA pivotal trials • Partner with large, established company for distribution outside the US • In house dire
Slide 8: Hemostat/Sealant Markets are Large and Growing
Hemostat/Sealant Markets are Large and Growing • Broad indication creates robust opportunity to capture both the hemostats and the fibrin and other sealants markets • $5.5 billion global combined market in 2015 • CAGR 8.69% 2010 - 2017 Global Hemostats, Fibrin & Other Sealants 8 7 6 Billions USD 5 4
Slide 9: Problem: Every Sealant Out There Has Limitations
Problem: Every Sealant Out There Has Limitations There are more than 30 companies worldwide with hemostats or sealants, driving a global market of $5.5 billion. Yet none of the current products are optimal, as they do not address complex high pressure bleeding, are difficult to prepare or take a lon
Slide 10: And For Some Procedures There is Nothing
And For Some Procedures There is Nothing Tissue Bleeding Vascular Anastomotic Bleeding Fibrin Gels Powdered Complex Fibrin • Bone • Organ Injuries • Avulsion Flowables wounds Nothing Aqueous Thrombin Synthetic Sealants Simple • Skin • Tissue flaps • Graft Mechanical Patches surfaces Hemostats Mild M
Slide 11: The Xcede Patch Works Better Everywhere
The Xcede Patch Works Better Everywhere …. Tissue Bleeding Vascular Anastomotic Bleeding Complex Even here • Bone • Organ Injuries • Avulsion wounds Xcede Patch Simple works in all indications • Skin • Tissue flaps • Graft surfaces Mild Moderate Low pressure High pressure 11
Slide 12: And Outperforms the Competition
And Outperforms the Competition Characteristic Xcede Patch Evarrest™ Tachosil™ Surgeon hold time 15 seconds 3 minutes 3 minutes Stops severe arterial bleeding XX No Thrombin XX Flexible to fit complex wounds X Long shelf life at room temp X X X Effective on junctional wounds X X High burst resistanc
Slide 13: Video
Video https://youtu.be/4VeuOOKGD9g 13
Slide 14: Xcede Patch Pre-Clinical Work to Date
Xcede Patch Pre-Clinical Work to Date Animal Studies 65 acute animals; 18 survival animals: vascular sealing, intramuscular and subcutaneous implant Preclinical studies have shown superior performance in many applications: Spleen and liver hemostasis Partial nephrectomy hemostasis Lung sea
Slide 15: Intellectual Property Portfolio – Protection from Competition
Intellectual Property Portfolio – Protection from Competition Filing Patent name Summary Status date Composition – components of Tissue Patch Allowed 10/4/2012 patch and primer Systems and Methods for the Engineering – steps to make patch Published 10/4/2012 fabrication of tissue patches and primer
Slide 16: An Industry with Momentum-Hemostat/Sealant Market is Flush with Acquisition Activity
An Industry with Momentum-Hemostat/Sealant Market is Flush with Acquisition Activity Company/Product Partner Date Status at acquisition Acquisition Amount RecoThrom The Medicines 2012/ FDA approved $105 million collaboration fee, $10 Company 2014 million option with purchase price based on Net Reven
Slide 17: Xcede Technologies’ Funding History
Xcede Technologies’ Funding History 2015 2014 Explore Angel funding options for 2013 of $2 million in further external the form of funding. Xcede Technologies convertible formed. Mayo notes 2011 – 2013 becomes a Dynasil Shareholder Biomedical (DBM) funds Tissue Sealant technology. 17
Slide 18: Dynasil’s Strategic Objectives for Xcede
Dynasil’s Strategic Objectives for Xcede •Attract long-term biotech investors to Xcede to fund its future. •Preserve Dynasil’s equity position/investment in Xcede, so that Dynasil’s stockholders share in the upside. •De-consolidate Xcede from Dynasil so Xcede’s losses are no longer on Dynasil’s fina
Slide 19: Summary
Summary • Xcede has game changing technology with unique hemostatic and sealant properties • Superb team and partners • Partnership with Mayo Clinic • Experienced management • Large and growing market • Robust IP position • Active acquisition landscape in Hemostat and Sealant market 19
Slide 20: Xcede Technologies, Inc. Dynasil Corporation of America Annual Meeting of Stockholders
Xcede Technologies, Inc. Dynasil Corporation of America Annual Meeting of Stockholders Peter Sulick, Chairman, President and CEO February 26, 2015
Dynasil Corporation of America — Shareholder Meeting (February 2015) on 6ix